MEDBOT-B (02252) rose more than 4%. As of the time of writing, the stock was up 4.01% to HK$32.16, with a turnover of HK$862 million. The company announced last night that it expects revenue for the fiscal year ended December 31, 2025, to increase by approximately 110% to 120% year-on-year. Its adjusted net loss is projected to be no more than RMB 240 million, representing a reduction of over 50% compared to the previous year. As of the announcement date, Toumai has accumulated over 180 commercial orders globally, with total commercial installations surpassing 120 units. Notably, on January 20, the National Healthcare Security Administration issued the "Guidelines for Establishing Price Items for Surgical and Therapeutic Auxiliary Operation Medical Services (Trial)", which established a unified national pricing framework for innovative medical technologies such as surgical robots, specialized consumables for energy devices, and remote surgery. Everbright Securities believes the surgical robot industry has substantial potential and low penetration rates, and the increased policy clarity provides new momentum for industry growth.